-
New Patented Medicine Regulations will limit access to drugs for rare disorders. »
-
Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs. »
-
Coverage of new medicines in Federal-Provincial public drug plans 2009-2018 »
-
Coverage of new medicines in private versus public drug plans in Canada 2009-2018. »
-
Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB. »
-
Medical resources and spending across provincial healthcare systems in Canada. »
-
HTA and public coverage of new mental health drugs in Quebec and Canada. »
-
Medical Resources in Canada and OECD countries. »
-
Evidence that innovative medicines improve health and economic outcomes. »
-
Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options. »
-
Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018. »
-
Facts about the cost of patented drugs in Canada: 2018 Edition. »
-
VIDEO - National Pharmacare Facts. »
-
Out-of-pocket prescription drug costs: What are the implications for National Pharmacare? »
-
How much will National Pharmacare cost taxpayers? »
-
Is Canada under-investing in the use of medical devices? »
-
Who needs pharmacare? All Canadians are covered under existing private and public drug plans. »
-
Expertise gaps on Canada’s HTA advisory committees »
-
Consequences of over-regulating the prices of new drugs in Canada »
-
Costs without benefits for patients? Non-medical spending in Canada’s public health system »
-
Does Canada need a Patented Medicine Prices Review Board? »
-
The fiscal burden of provincial government health spending across Canada »
-
Abuse deterrent formulations for all prescription opioids could save $billions in societal costs »
-
Hospital spending compared across Canada’s Provinces »
-
HTA and delays to accessing mental health drugs in Canada »
-
Fewer treatment options for patients if Canada adopts New Zealand's prescription drug policies »
-
Governments could save $5 billion annually by allowing modest user charges for physician services »
-
How long do new patented medicines have market exclusivity in Canada’s public drug plans? »
-
What is the cost of physicians across Canada by province? »
-
Economic cost of lost health gains from delayed access to 14 new cancer drugs. »
-
Capturing value for patients: HTA and the utility-expansion of new cancer drugs. »
Latest
-
New Patented Medicine Regulations in Canada: Updated Case Study. (EN/FR)
PMPRB’s draft guidelines will limit access to drugs for rare disorders. »
-
New drug submissions in the United States and Canada 2014-2019: trends and policy implications.
Canada may have passed a tipping point where we are no longer considered a premier jurisdiction to launch new medicines. »
-
Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs.
U.S. importation impact on the Canadian drug supply will affect specific patient populations differently; the Canadian drug supply cannot sustain increased demand from Americans. »
-
New pathways for U.S. importation threaten Canadian prescription drug supply.
Serious drug shortages are predicted unless Canada puts a halt to exporting drugs to the U.S. »
-
Preventive care of the future? Economic analysis of cardiovascular risk management.
Some innovative medical clinics provide an alternative to the traditional curative care provided in the public health system, especially in hospitals. »
-
The costs of Immunoglobulin treatment in hospital and in the home in Quebec
Study examines the improvements in cost and quality of service arising from administration of Ig treatments in the home as opposed to in a hospital setting. »
-
Coverage of new medicines in Federal-Provincial public drug plans in Canada 2009-2018
Data reflect poorly on prospects for national pharmacare and the performance of the pan-Canadian Pharmaceutical Alliance (pCPA). »
-
Coverage of new medicines in private versus public drug plans in Canada 2009-2018
Public plans cover far fewer new drugs compared to private plans in Canada. Public plans also take much longer to cover new drugs compared to private plans. »
-
Clinical Duty to Recontact in Genetic Testing: Insights from the Safety-Related Duty to Recall.
When the understanding of relevant science no longer supports prior interpretation of a test result, is there a duty to recontact previously tested patients to inform them of the implications of these changes? »
